{
"indication": {
"drug": "Avelumab (Bavencio)",
"disease": "Metastatic/Advanced Urothelial Carcinoma",
"line": "First-line",
"setting": "After platinum chemotherapy without progression",
"last_updated": "2025-01-17",
"updated_by": "EMD Serono Competitive Intelligence Tool"
},
"direct_competitors": [
{
"drug": "Enfortumab vedotin + Pembrolizumab",
"line_of_therapy": "1L",
"company": "Astellas/Seagen/Merck",
"moa": "Nectin-4 ADC + PD-1 inhibitor",
"trials": "EV-302/KEYNOTE-A39 (median OS 34 months vs 16.1 months for chemo)",
"threat_level": "HIGH",
"rationale": "New 1L standard of care with unprecedented survival benefit, FDA approved Dec 2023",
"keywords": ["enfortumab", "vedotin", "padcev", "pembrolizumab", "keytruda", "pembro", "EV-302", "EV302", "EV 302", "KEYNOTE-A39", "KEYNOTE A39", "A39", "EV+P", "EV+pembro", "EV-P", "EVP", "UNITE", "EV-103", "EV103", "KEYNOTE-905"]
},
{
"drug": "Durvalumab + chemotherapy (perioperative)",
"line_of_therapy": "1L",
"company": "AstraZeneca",
"moa": "PD-L1 inhibitor + chemotherapy",
"trials": "NIAGARA (EFS HR 0.68, OS HR 0.75)",
"threat_level": "MEDIUM",
"rationale": "Perioperative approach for cisplatin-eligible MIBC patients, FDA PDUFA Q2 2025",
"keywords": ["durvalumab", "imfinzi", "NIAGARA", "perioperative", "neoadjuvant"]
},
{
"drug": "Nivolumab + gemcitabine-cisplatin",
"line_of_therapy": "1L",
"company": "Bristol Myers Squibb",
"moa": "PD-1 inhibitor + chemotherapy",
"trials": "CheckMate-901 (OS HR 0.78 vs chemo)",
"threat_level": "MEDIUM",
"rationale": "Alternative 1L option for cisplatin-eligible patients, less effective than EV+P",
"keywords": ["nivolumab", "opdivo", "CheckMate-901", "gemcitabine", "cisplatin"]
}
],
"emerging_threats": [
{
"drug": "Sacituzumab govitecan",
"company": "Gilead",
"moa": "Trop-2 ADC",
"phase": "Withdrawn from bladder cancer",
"biomarker": "None required",
"threat_level": "LOW",
"keywords": ["sacituzumab", "trodelvy", "TROPiCS-04", "TROPHY-U-01", "trop-2"]
},
{
"drug": "Erdafitinib",
"company": "Johnson & Johnson",
"moa": "FGFR inhibitor",
"phase": "FDA approved",
"biomarker": "FGFR3/2 alterations (20% prevalence)",
"threat_level": "LOW",
"keywords": ["erdafitinib", "balversa", "FGFR", "FGFR3", "THOR", "biomarker"]
},
{
"drug": "Tisotumab vedotin",
"company": "Genmab/Seagen",
"moa": "Tissue factor ADC",
"phase": "Phase 2",
"biomarker": "Tissue factor expression",
"threat_level": "LOW",
"keywords": ["tisotumab", "tivdak", "tissue factor", "InnovaTV", "ADC"]
}
],
"key_biomarkers": [
{
"biomarker": "PD-L1 expression",
"clinical_utility": "Historical predictor of ICI response, less relevant with current combinations",
"prevalence": "~50% in urothelial cancer",
"keywords": ["PD-L1", "CPS", "combined positive score", "tumor proportion score"]
},
{
"biomarker": "FGFR3/2 alterations",
"clinical_utility": "Predictor for erdafitinib response",
"prevalence": "20% overall, 36% in upper tract",
"keywords": ["FGFR3", "FGFR2", "mutations", "fusions", "alterations"]
},
{
"biomarker": "Nectin-4 expression",
"clinical_utility": "Target for enfortumab vedotin, ubiquitously expressed",
"prevalence": ">90%",
"keywords": ["nectin-4", "nectin", "PVRL4", "enfortumab target"]
}
],
"paradigm_shifts": [
{
"old": "Platinum chemotherapy followed by switch maintenance with avelumab",
"new": "Enfortumab vedotin + pembrolizumab as first-line regardless of cisplatin eligibility",
"impact": "Avelumab maintenance becomes second-line option after EV+P failure",
"year": "2023-2024"
},
{
"old": "Sequential therapy approach",
"new": "Combination ADC + ICI upfront",
"impact": "Reduces eligible patient pool for avelumab maintenance",
"year": "2024-2025"
},
{
"old": "PD-L1 as key biomarker",
"new": "Biomarker-agnostic combinations (EV+P)",
"impact": "Diminishes importance of PD-L1 testing for treatment selection",
"year": "2023-2025"
}
],
"exclusions": {
"settings": ["Non-muscle invasive bladder cancer", "Adjuvant/neoadjuvant monotherapy", "Second-line after progression"],
"rationale": "Focus only on 1L maintenance setting after platinum chemotherapy without progression"
}
}